PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
Basel-based medtech company Medartis plans to conduct an initial public offering (IPO) on the SIX Swiss Exchange in the first half of 2018 to finance its further growth. The IPO also underscores the company’s commitment to its facilities in Basel.
Medartis manufactures titanium implants and instruments for the surgical treatment of bone fractures and osteotomies. With its products sold in 44 countries worldwide, the Basel-based company also has a pipeline of additional products that it plans to bring to the market over the course of this year and next.
Medartis intends to finance this growth with an IPO.
“The planned IPO will mark an important milestone in the development of Medartis and will allow us to take the company to the next level,” Thomas Straumann, founder and chairman of Medartis, said in a statement.
“There are numerous opportunities for us to grow, and the timing is right for us to offer shares and seek a listing.”
Medartis employs over 480 people across its 11 locations, 220 of whom work at its headquarters in Basel. The company also has a 5,000-square-metre manufacturing facility in Basel. Working under one roof in Basel makes it easier for Medartis to efficiently bring new products to the market.
The planned IPO will help finance Medartis’ growth and further raise its profile in the orthopaedic field. The medtech company also says that the IPO “underscores” its Swiss heritage and commitment to the Swiss market.
“Over the last 20 years, we have managed to build a company with a unique portfolio of implant systems combined with deep relationships with our customers, who are highly valued,” said CEO Willi Miesch.
“With the planned IPO, we can continue to invest in these relationships, in developing new ones, and in expanding further into untapped geographies and additional indications.”